[Histopathologic validation of the tissue-microarray technology of urothelial cancer. Our experience].
BACKGROUND
The array technology offers: a big advance to clinic and basic investigator, it provides a variety of technics (immunohistochemistry, FISH, proteomics) to understand the molecular mechanisms of cancer. It offers scale economy in reagents versus the conventional methods. Array most be ratified because the sample is so reduced.


METHODS
52 consecutive cases have been chosen from paraffin blocks of bladder and ureteral cancer which are 5-7 years old, a tissue array has been made; disks have been arranged in lines and columns, in an aleatory way, in order to guide it's reading. It has been evaluated by a pathologist with any relation to specimen selection.


RESULTS
87 sheets ha been obtained. Number 1 has been dyed with HE. Has been discrepancy in 27% of sample's stage. Has not been a discrepancy in histopathologic diagnostic. There is no sample's representation in 11 points (17%).


CONCLUSIONS
Our results offer good results in sample's validation. The sample's antigenicity of tissue is conserved. Array sample's represent a 97%, similarly to all unit of conventional sections of the specimen.
Laborda Rodríguez
A
A
Servicio y Cátedra de Urología, Hospital del Mar, Universitat Autónoma de Barcelona-Universitat Pompeu Fabra.
Vallmanya Llena
F
F
Cortadellas Angel
R
R
Lloreta Trull
J
J
Gelabert Mas
A
A
D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D014516:Ureteral Neoplasms / Q000235:genetics* / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology*